Author | Komal Jhaveri, MD | OncLive

Author | Komal Jhaveri, MD


Dr. Jhaveri Discusses the Potential of Immunotherapy in TNBC

February 22, 2019


Komal Jhaveri, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the potential for immunotherapy in the treatment of patients with triple-negative breast cancer (TNBC) based on results from the IMpassion130 trial.

Antibody-Drug Conjugates and T-DM1

March 21, 2014


Human epidermal growth factor receptor 2 (HER2)-positive disease accounts for 20% to 25% of breast cancers, as represented by amplification of the HER2 gene and/or HER2 protein overexpression